1stOncology™: Cancer Intelligence Service – Page 12942 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Neuralstem Closes $7.5 Million Underwritten Public Offering

On July 31, 2019 Neuralstem, Inc. (Nasdaq: CUR) ("Neuralstem" or the "Company") reported the closing of its underwritten public offering of an aggregate of 2,777,777 units at a public offering price of $2.70 per unit resulting in gross proceeds of approximately $7,500,000, before deducting discount, commissions and estimated offering expenses (Press release, Neuralstem, JUL 31, 2019, View Source [SID1234537950]). Each unit issued was comprised of one share of common stock (or common stock equivalent), one short-term warrant to purchase one share of common stock and one long-term warrant to purchase one share of common stock (collectively, a "warrant combination"). The Company also granted the underwriters a 45-day option to purchase up to an additional 416,666 shares of common stock and/or additional 416,666 warrant combinations at the public offering price per share and per warrant combination of $2.70, before deducting underwriting discounts and commissions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

H.C. Wainwright & Co. acted as the sole book-running manager for the offering.

Each short-term warrant has an exercise price of $2.70 per share, is exercisable immediately and terminates on December 31, 2020. Each long-term warrant has an exercise price of $2.70 per share and is exercisable immediately for five years from the issuance date. The shares of common stock (or common stock equivalents), the short-term warrants and long-term warrants comprising the units will be immediately separable upon issuance and will be issued separately.

The securities described above were offered by the Company pursuant to a registration statement (file no. 333-232273) previously filed with and declared effective by the Securities and Exchange Commission (the "SEC") on July 25, 2019. The offering was made only by means of a prospectus forming part of the effective registration statement. A final prospectus relating to the securities being offered has been filed with the SEC and is available on the SEC’s website at www.sec.gov. Electronic copies of the final prospectus relating to the offering may be obtained from H.C. Wainwright & Co., LLC, 430 Park Avenue, 3rd Floor, New York, NY 10022, by telephone at (646) 975-6996 or by email at [email protected], or at the SEC’s website at www.sec.gov.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

BioInvent Announces Selection of First Target Discovered by BioInvent’s Proprietary F.I.R.S.TTM Technology Platform Under Collaboration With Pfizer Inc.

On July 31, 2019 BioInvent International AB ("BioInvent" or the "Company") (OMXS: BINV) reported that Pfizer Inc. ("Pfizer") (NYSE: PFE) has selected the first target under the companies’ cancer immunotherapy research collaboration and license agreement, into which the companies entered in December 2016 to develop antibodies targeting tumor-associated myeloid cells (Press release, BioInvent, JUL 31, 2019, View Source [SID1234537949]).

The selection of a target triggers a payment from Pfizer to BioInvent of $300,000. Under the terms of the 2016 agreement, potential selection and development of antibodies directed against this target, as well as potential selection of further targets and development of antibodies directed at them, would allow BioInvent to be eligible for further milestone payments.

Martin Welschof, CEO of BioInvent, said: "Selection of this first target shows that our collaboration with Pfizer is successfully progressing. We believe this is an important validation of our F.I.R.S.TTM technology platform, which is a patient-centric approach allowing for the discovery of human antibodies and targets using our high-quality n-CoDeR antibody library."

Affimed Announces Second Quarter 2019 Financial Results and Corporate Update Conference Call on August 7, 2019

On July 31, 2019 Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer, reported that it will host a conference call on Wednesday, August 7, 2019 at 8:30 a.m. ET to discuss its second quarter 2019 financial results and recent corporate developments (Press release, Affimed, JUL 31, 2019, View Source [SID1234537948]).

The conference call will be available via phone and webcast. To access the call, please dial +1 917 7200 178 for U.S. callers, or +44 (0) 203 0095710 for international callers, and reference conference ID 9396039 approximately 15 minutes prior to the call.

An audio webcast of the conference call can be accessed in the "Webcasts" section on the "Investors" page of the Affimed website at View Source A replay of the webcast will be available on Affimed’s website shortly after the conclusion of the call and will be archived for 30 days following the call.

SELLAS Advances Galinpepimut-S (GPS) in Combination with KEYTRUDA® (pembrolizumab) Program with Dosing of First Patient in Phase 1/2 Basket Study

On July 31, 2019 SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) ("SELLAS" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, reported the dosing of the first patient in its Phase 1/2 open-label study of GPS in combination with Merck’s anti-PD-1 therapy KEYTRUDA (pembrolizumab), in patients with selected WT1-positive advanced cancers, including both solid tumors and hematologic malignances (Press release, Sellas Life Sciences, JUL 31, 2019, View Source [SID1234537945]).

"This is an important milestone as this study allows us to potentially enhance our safety and activity profile of GPS in combination with anti-PD-1 therapies, particularly in combination with KEYTRUDA in multiple malignances, following intriguing initial combination clinical data with OPDIVO," said Angelos M. Stergiou, M.D., ScD h.c., President and Chief Executive Officer of SELLAS. "We are confident this study will build on our body of clinical evidence in support of the use of GPS in combination with PD-1 inhibitors to benefit cancer patients with limited treatment options. We believe that our innovative WT1 immunotherapeutic, GPS, in combination with anti-PD-1 immunotherapy agents, may provide therapeutic benefit for patients with WT1 expression. These beliefs are shared by the renowned U.S. oncologists who are undertaking this work. We look forward to studying this combination in patients with a wide range of cancers and expect to provide the first clinical data from this study in the first quarter of 2020."

The Company also announced today that Richard Maziarz, M.D., Medical Director of the Adult Blood and Marrow Stem Cell Transplant & Cellular Therapy Program at the Knight Cancer Institute and Professor of Medicine at Oregon Health and Science University (OHSU) in Portland, OR, and Roisin O’Cearbhaill, M.D., Assistant Attending Physician in Gynecologic Medical Oncology Service at the Memorial Sloan Kettering Cancer Center (MSKCC), are serving as co-principal investigators for this study.

About the Study
The Phase 1/2 open-label, multicenter, multi-arm study is being conducted under a Clinical Trial Collaboration and Supply Agreement (CTSA) with Merck (known as MSD outside the United States and Canada) to assess the efficacy and safety of the combination of GPS and KEYTRUDA.

The primary endpoints of the study include safety and overall response rate, while secondary endpoints include progression-free survival, overall survival and immune response correlates. The study will enroll approximately 90 patients at up to 20 centers in the United States. The trial is initially evaluating patients with ovarian cancer (second or third line) and colorectal cancer (third or fourth line), to be followed by patients with acute myeloid leukemia (AML) who are unable to attain deeper morphological response than partial on hypomethylating agents and who are not eligible for allogeneic hematopoietic stem cell transplant and patients with triple negative breast cancer (TNBC) (second line), and small cell lung cancer (second line).

Keytruda is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., USA., and is not a trademark of SELLAS. The manufacturer of this brand is not affiliated with and does not endorse SELLAS or its products.

Selecta Biosciences to Present at Canaccord Genuity’s 39th Annual Growth Conference on August 7, 2019

On July 31, 2019 Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR, reported that CEO and President Carsten Brunn, Ph.D., will participate in a fireside chat at Canaccord Genuity’s 39th Annual Growth Conference in Boston, Mass. at 1:00 p.m. ET on Wednesday, August 07, 2019 (Press release, Selecta Biosciences, JUL 31, 2019, View Source [SID1234537944]). A live and archived webcast of the presentation will be available on the Investors & Media section of the Selecta website at www.selectabio.com.